Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Die angezeigten Daten werden derzeit aktualisiert.
Exportieren
Filter
  • American Association for Cancer Research (AACR)  (2)
  • 1
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 82, No. 12_Supplement ( 2022-06-15), p. 2502-2502
    Kurzfassung: The genetic landscape of post-transplant lymphoproliferative disorders (PTLD) in pediatric population has not been fully elucidated. This absence of information raises the question whether therapeutic strategies should be the same as for their counterparts in immunocompetent (IC) patients. The aim of this study was to characterize genetically and immunophenotypically pediatric monomorphic PTLD. Thirty-nine monomorphic PTLD ≤19 years-old (mean 10y, gender 25 male/14 female) were recruited and analyzed for germinal center markers, IRF4 and EBER expression. Presence of MYC, PAX5, IRF4, BCL2, BCL6 and 11q alterations was investigated by FISH. Additional molecular studies included clonality, copy number (CN) arrays, cell of origin-COO (Nanostring) and mutational analyses (Custom 167 lymphoma related genes panel, SureSelectXT, Agilent). Twenty-nine patients received solid organ transplantation and eight were hematopoietic stem cell transplant recipients. The mean time from transplant to PTLD diagnosis was 34 months (range 2-170) and the estimated 5-year overall survival (5y-OS) rate was 67%. Patients that received a solid organ had a better prognosis than hematopoietic stem cell transplant recipients (5y-OS 83% vs. 38%, p=0.03). Thirty-three cases were classified as diffuse large B-cell lymphoma (DLBCL) and six as Burkitt lymphoma (BL). Thirty-two cases had extranodal localization, 21 of which in the gastrointestinal tract. Among the DLBCL, 24/28 cases had an ABC/non-GC COO phenotype and the six BL were GCB. EBER was positive in 33/37 cases. Five out of six BL and one DLBCL had MYC rearrangements, while no 11q alterations or other rearrangements were observed. Ten out of the 23 pediatric monomorphic PTLD studied displayed CN alterations (mean 1.6 alt/case; range 0-12). Comparative analyses showed that pediatric PTLD had lower genetic complexity than BL (Scholtysik, 2010) and DLBCL (Ramis-Zaldivar, 2020) in IC patients and adult-PTLD (Ferreiro, 2016; Rinaldi, 2010) and lacked characteristic CN alterations of those groups. Regarding the mutational profile, all 6 PTLD-BL carried MYC mutations in addition to ID3 (4 cases), ARID1A (2 cases) or CCND3 (1 case) and a higher mutational burden than PTLD-DLBCL (12.3 vs 6.2, p=0.01). PTLD-DLBCL showed a very heterogeneous profile characterized by a lower number of mutations than their counterparts in IC patients (2.4 vs 6.5, p=0.01). Pathway enrichment analysis revealed that epigenetic modifiers and NOTCH pathway (4 cases each) were the most recurrently affected. Two out of 20 cases were classified as N1 according to LymphGen (Wright, 2020) algorithm while the rest remained undetermined. The mutational profile of pediatric PTLD-BL is similar to that observed in IC patients whereas PTLD-DLBCL are less complex than their counterpart in IC children and present a very heterogeneous mutational landscape with enrichment in NOTCH pathway mutations. Citation Format: Julia Salmeron, Natalia Castrejón-de-Anta, Pilar Guerra-Garcia, Joan Enric Ramis-Zaldivar, Mónica López-Guerra, Dolors Colomer, Francisco Diaz-Crespo, Marta Garrido, Javier Menarguez, Maria del Mar Andrés, Eugenia Garcia-Fernandez, Margarita Llavador, Noelia Garcia, Blanca Gonzalez-Farré, Idoia Martin-Guerrero, Carmen Garrido, Itziar Astigarraga, Alba Fernández, Jaime Verdú-Amorós, Soledad González-Muñíz, Berta Gonzalez, Verónica Celis, Elias Campo, Olga Balagué, Itziar Salaverria. Unravelling the heterogenous molecular landscape of pediatric post-transplant lymphoproliferative disorders [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2502.
    Materialart: Online-Ressource
    ISSN: 1538-7445
    Sprache: Englisch
    Verlag: American Association for Cancer Research (AACR)
    Publikationsdatum: 2022
    ZDB Id: 2036785-5
    ZDB Id: 1432-1
    ZDB Id: 410466-3
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    Online-Ressource
    Online-Ressource
    American Association for Cancer Research (AACR) ; 2020
    In:  Cancer Research Vol. 80, No. 4_Supplement ( 2020-02-15), p. P1-17-11-P1-17-11
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 4_Supplement ( 2020-02-15), p. P1-17-11-P1-17-11
    Kurzfassung: Background: It is widely recognized that women's sexuality can be particularly complex during the treatment of breast cancer. This, in turn, has physical, emotional and psychological consequences throughout the life of these patients. However, there is limited information regarding sexual health in Hispanic women with breast cancer. The objective of this study was to evaluate sexual dysfunction in Mexican women with breast cancer who were receiving active treatment against cancer. Methods: We prospectively evaluated sexual dysfunction among Mexican patients with breast cancer receiving active oncological treatment at a single institution in Mexico City using the Spanish language version of the Female Sexual Function Index (FSFI). FSFI is graded as a continuous scale from 2-36, and is formed of 6 subscales (desire, arousal, lubrication, orgasm, satisfaction, and pain) with a maximal score of 6 each. Sexual dysfunction was defined as an FSFI & lt;26.55 points. Demographic and clinical data were collected from the clinical record and analyzed using descriptive statistics. Fisher's exact tests were used for comparisons among groups. Results: 84 women with breast cancer undergoing active treatment completed the FSFI. Median age was 57 years (range 25-87), 59.2% were postmenopausal, and 46.4% were married. Median body mass index (BMI) was 25.2. 60% of patients had early stage breast cancer (Stage 0-II), 64% were receiving hormonal treatment (average duration of 28.3 months), and 25% were undergoing treatment with chemotherapy. 42% had undergone breast conserving surgery, while 28% had received a mastectomy. 51 patients (60.7%) reported absence of sexual activity during the previous four weeks. Patients who reported sexual activity in the previous four weeks had a mean FSFI score of 23 points (range 15.7-44) and 63.6% had sexual dysfunction. Subscale scores were as follows: desire 1.7 (range 1.2-2.4), arousal 2.9 (range 1.5-5.1), lubrication 3.1 (range 1.5-4), orgasm 3.6 (range 1.1-4.8), satisfaction 4.0 (range 1.2-5.6), and pain 2.5 (range 1.2-5.2). Premenopausal women were more likely than postmenopausal women to report sexual dysfunction (85% vs. 44%, p = 0.02) with a mean FSFI score of 20.9 and 17.3 respectively. Among postmenopausal women with sexual dysfunction, the lowest scores were found in the desire (1.72) and pain domains (2.5). Desire (3.2) and lubrication (3.27) were the domains with the lowest scores among premenopausal patients. Sexual dysfunction was not related to the type of breast surgery (mastectomy vs breast conserving, p = 0.26). Conclusions: Our study shows a significant proportion of Mexican women with breast cancer have sexual dysfunction and absence of sexual activity. Premenopausal patients were more frequently affected, particularly in the desire and lubrication domains, while postmenopausal women reported poor desire and pain. This provides valuable information to design innovative strategies aimed at improving the sexual health and quality of life of patients diagnosed with breast cancer undergoing active oncological treatments. Citation Format: Mónica Lily Cordón-Paz, Luis Lara-Mejía, Ana Olvera-Cruz, Lorelí Mejía-Fernández, Pilar Milke-Garcia, Yanin Chavarri-Guerra. Sexual function in Mexican patients with breast cancer receiving active oncological treatment [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-17-11.
    Materialart: Online-Ressource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Sprache: Englisch
    Verlag: American Association for Cancer Research (AACR)
    Publikationsdatum: 2020
    ZDB Id: 2036785-5
    ZDB Id: 1432-1
    ZDB Id: 410466-3
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie auf den KOBV Seiten zum Datenschutz